Title

以健保資料庫分析藥物治療後影響甲狀腺亢進之因素

Translated Titles

Analysis of Factors Affecting Hyperthyroidism Relapse after Medical Treatment Using National Health Insurance Research Databases

DOI

10.6831/TMU.2012.00167

Authors

蔡昆原

Key Words

甲狀腺;健保資料庫 ; thyroid ; National Health Insurance Research Databases

PublicationName

臺北醫學大學醫學資訊研究所學位論文

Volume or Term/Year and Month of Publication

2012年

Academic Degree Category

碩士

Advisor

劉建財

Content Language

繁體中文

Chinese Abstract

本研究在研究以甲狀腺亢進接受藥物治療後復發的影響因子。抗甲狀腺藥物治療是台灣甲狀腺功能亢進最常用的治療方式。然而抗甲狀腺藥物治療需長期服藥而且治療後的復發率高。了解造成甲狀腺亢進復發的因子才能做出適當的臨床決策。本研究以1999-2008年全民健保資料庫的抽樣歸人檔為資料來源,整理甲狀腺亢進患者接受第一次藥物治療的資料進行分析。研究排除接受放射碘131,甲狀腺開刀,具有甲狀腺癌重大傷病診斷,與退保的病患,進行分析年齡,抗甲狀腺藥物治療模式,病患共患診斷對治療後的復發或緩解是否造成差異。結果:年齡12歲以下40歲以上與13-40歲(Log rank 0.00),抗甲狀腺藥物療程90天以下與大於90天(Log rank 0.00),抗甲狀腺藥物開藥天數90天以下與大於90天(Log rank0.00),抗甲狀腺藥物累積顆數365顆以下與大於365顆(Log rank0.00),與抗甲狀腺藥物平均每日劑量1顆以下,大於1顆且2顆以下,大於兩顆(Log rank 0.00)對病患的復發與緩解有差異。共病診斷如ICD-9CM 376(Log rank0.00),ICD-9CM 427(Log rank0.002),ICD-9CM 785(Log rank0.00),ICD-9CM 246(Log rank0.00),ICD-9CM 252(Log rank0.00),ICD-9CM 493(Log rank0.00)對復發與緩解有差異。 結論:以1999-2008年抽樣的台灣全民健保資料庫內抗甲狀腺藥物治療後的復發與緩解與年齡,抗甲狀腺藥物療程,抗甲狀腺藥物開藥天數,抗甲狀腺藥物累積劑量,抗甲狀腺藥物平均每日劑量,疾病診斷碼ICD-9CM 376,ICD-9CM 427,ICD-9CM 246,ICD-9CM 785,ICD-9CM 493,ICD-9CM 252有關。

Topic Category 基礎與應用科學 > 資訊科學
醫藥衛生 > 醫藥總論
醫學科技學院 > 醫學資訊研究所
Reference
  1. 1. 李帶琪,(台灣地區甲狀腺機能亢進治療型態之探討),臺灣大學預防醫學研究所,碩士論文,民98.
    連結:
  2. 12. Melmed S, Williams RH. Williams textbook of endocrinology. Chapter 11, 12th ed. Philadelphia: Elsevier/Saunders; 2011.
    連結:
  3. 2. Brent GA. Clinical practice. Graves' disease. N Engl J Med 2008;358:2594-605.
    連結:
  4. 3. Ajjan RA, Weetman AP. Medical Management of Hyperthyroidism. US endocrine disease 2007.
    連結:
  5. 4. Cooper DS. Hyperthyroidism. Lancet 2003;362:459-68.
    連結:
  6. 7. Ribeiro RC, Apriletti JW, West BL, et al. The molecular biology of thyroid hormone action. Annals of the New York Academy of Sciences 1995;758:366-89.
    連結:
  7. 8. Kasagi K, Takahashi N, Inoue G, Honda T, Kawachi Y, Izumi Y. Thyroid function in Japanese adults as assessed by a general health checkup system in relation with thyroid-related antibodies and other clinical parameters. Thyroid : official journal of the American Thyroid Association 2009;19:937-44.
    連結:
  8. 9. Flynn RW, MacDonald TM, Morris AD, Jung RT, Leese GP. The thyroid epidemiology, audit, and research study: thyroid dysfunction in the general population. J Clin Endocrinol Metab 2004;89:3879-84.
    連結:
  9. 11. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med 2003;348:2646-55.
    連結:
  10. 14. Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon DH. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA : the journal of the American Medical Association 1990;263:1529-32.
    連結:
  11. 15. Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 2006;35:663-86, vii.
    連結:
  12. 16. Werner SC, Ingbar SH, Braverman LE, Utiger RD. Werner & Ingbar's the thyroid : a fundamental and clinical text. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
    連結:
  13. 17. Young ET, Steel NR, Taylor JJ, et al. Prediction of remission after antithyroid drug treatment in Graves' disease. The Quarterly journal of medicine 1988;66:175-89.
    連結:
  14. 18. Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid : official journal of the American Thyroid Association 2011;21:593-646.
    連結:
  15. 19. Torring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996;81:2986-93.
    連結:
  16. 23. Bona G, Chiorboli E, Rapa A, Weber G, Vigone MC, Chiumello G. Measurement of urinary iodine excretion to reveal iodine excess in neonatal transient hypothyroidism. Journal of pediatric endocrinology & metabolism : JPEM 1998;11:739-43.
    連結:
  17. 24. Laurberg P, Cerqueira C, Ovesen L, et al. Iodine intake as a determinant of thyroid disorders in populations. Best practice & research Clinical endocrinology & metabolism 2010;24:13-27.
    連結:
  18. 25. Chuang CC, Wang ST, Wang PW, Yu ML. Prevalence study of thyroid dysfunction in the elderly of Taiwan. Gerontology 1998;44:162-7.
    連結:
  19. 26. Yamada T, Aizawa T, Koizumi Y, Komiya I, Ichikawa K, Hashizume K. Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves' disease. Journal of the American Geriatrics Society 1994;42:513-6.
    連結:
  20. 27. Schleusener H, Schwander J, Fischer C, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta endocrinologica 1989;120:689-701.
    連結:
  21. 29. Maugendre D, Gatel A, Campion L, et al. Antithyroid drugs and Graves' disease--prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 1999;50:127-32.
    連結:
  22. 30. Miehle K, Paschke R. Therapy of hyperthyroidism. Exp Clin Endocrinol Diabetes 2003;111:305-18.
    連結:
  23. 31. Romaldini JH, Bromberg N, Werner RS, et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983;57:563-70.
    連結:
  24. 32. Grebe SK, Feek CM, Ford HC, et al. A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin Endocrinol (Oxf) 1998;48:585-92.
    連結:
  25. 33. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362:726-38.
    連結:
  26. 35. Cho SB, Kim JH, Cho S, Park JM, Park YK, Oh SH. Vitiligo in children and adolescents: association with thyroid dysfunction. Journal of the European Academy of Dermatology and Venereology : JEADV 2011;25:64-7.
    連結:
  27. 36. Shong YK, Kim JA. Vitiligo in autoimmune thyroid disease. Thyroidology / APRIM 1991;3:89-91.
    連結:
  28. 37. Kasumagic-Halilovic E, Prohic A, Begovic B, Ovcina-Kurtovic N. Association between Vitiligo and Thyroid Autoimmunity. Journal of thyroid research 2011;2011:938257.
    連結:
  29. 38. Chu SY, Chen YJ, Tseng WC, et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. Journal of the American Academy of Dermatology 2011;65:949-56.
    連結:
  30. 39. Antonelli A, Fallahi P, Mosca M, et al. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism: clinical and experimental 2010;59:896-900.
    連結:
  31. 41. Wimmersberger Y, Zuercher D. Graves' disease associated with primary systemic sclerosis. Orbit 2009;28:262-3.
    連結:
  32. 42. Yue WS, Chong BH, Zhang XH, et al. Hyperthyroidism-induced left ventricular diastolic dysfunction: implication in hyperthyroidism-related heart failure. Clin Endocrinol (Oxf) 2011;74:636-43.
    連結:
  33. 43. Sheu JJ, Kang JH, Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke; a journal of cerebral circulation 2010;41:961-6.
    連結:
  34. 44. Benito L, Hoyo J, Montroig A, et al. Adverse effects of antiarrhythmic drugs in patients with atrial fibrillation in primary care. Medicina clinica 2011;137:241-6.
    連結:
  35. 47. Rosner B. Fundamentals of Biostatistics, 5th ed. (2000).
    連結:
  36. 中文文獻
  37. 5. 林宏達,(認識甲狀腺),文史哲出版社,民71.
  38. 48. 林建甫,(存活分析) ,Page 1-13,雙業書局,民97.
  39. 13. 林宏達,(甲狀腺高能症Hyperthyroidism),臨床醫學,民73;14卷:512-7.
  40. 20. 楊宏智,(甲狀腺機能亢進症之治療),臨床醫學,民84;36:162-67.
  41. 46. 姚素俐,(甲狀腺切除術後醫療利用與醫療品質相關因素之探討),國立陽明大學醫務管理研究所,碩士論文,民94.
  42. 英文文獻
  43. 6. Marieb EN, Mallatt J, Wilhelm PB. Human Anatomy: Media Update: Benjamin-Cummings Publishing Company; 2009.
  44. 10. Chang TC, Wang CY, Lu CP, Hong MC, Wang PD. Prevalence of goiter in school children in the Wan-Hwa district of Taipei. Journal of the Formosan Medical Association 1995;94:193-6.
  45. 21. Hsieh YH, Yang CF, Chen KP, Lee TY, Hsu PY. Studies of the effect of the salt iodization on endemic goiter in Taiwan. 3. Urinary iodine excretion of school children. Journal of the Formosan Medical Association 1973;72:218-23.
  46. 22. Lin HD, Lo JG, Ching KN. Amount of urinary iodine excretion in residents of Taipei City--a hospital-based study. Chinese medical journal; Free China ed 1991;48:20-4.
  47. 28. Chiou SC, Houng HS, Li KL, et al. Outcome of Graves' thyrotoxicosis after antithyroid drug treatment. Chang Gung medical journal / Chang Gung Memorial Hospital 1995;18:305-14.
  48. 34. Eckstein A, Esser J, Mann K, Schott M. Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy. Pediatric endocrinology reviews : PER 2010;7 Suppl 2:198-203.
  49. 40. Weiss M. Why in rheumatic patients you should think about the thyroid gland, too. Autoimmune diseases often come in double pack. MMW Fortschritte der Medizin 2008;150:10-1.
  50. 45. Kandler H, Brendel B. Diabetes mellitus and hyperthyroidism. Padiatrie und Grenzgebiete 1983;22:419-24.
  51. 電子資料
  52. 49 醫療費用支付標準碼. http://www.nhi.gov.tw/query/query2.aspx?menu=20&menu_id=710&webdata_id=3633&WD_ID=900
  53. 附件: 抗甲狀腺藥物藥物療程資料